Hereditary Angioedema Therapeutics Market Growth Outlook: Trends, Market Size, and Opportunities Over the Next Decade
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What Drivers Are Shaping the Growth and Development of theHereditary Angioedema Therapeutics Market?
The increasing incidence of hereditary angioedema is anticipated to spur the expansion of the hereditary angioedema market in the future. Hereditary angioedema (HAE) is an uncommon genetic condition that is defined by frequent bouts of serious swelling of the skin and mucous membranes. This swelling is due to an excessive build-up of fluid (EDEMA) and can happen anywhere in the body, such as the hands and feet, face, intestines, and airways. For instance, in June 2022, Rare Disease Advisor, a digital health resource company, reported that globally, 1 in every 50,000 individuals is affected by hereditary angioedema, with prevalence estimates ranging from 1:10,000 to 1:150,000. Annually in the US, HAE episodes result in 15,000 to 30,000 emergency room visits. 5.8% of hereditary angioedema cases had an average diagnostic time of 0 to 6 months, and another 5.8% had an average diagnostic time of over 10 years. Therefore, the escalating incidence of hereditary angioedema fuels the growth of the hereditary angioedema market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp
What is the Predicted Annual Growth Rate of theHereditary Angioedema Therapeutics Market Impact Industry Trends by 2034?
The market size for hereditary angioedema therapeutics has seen a significant expansion in the recent past. It is projected to increase from $6.68 billion in 2024 to $7.84 billion in 2025, registering an impressive compound annual growth rate (CAGR) of 17.3%. This growth during the historic period is credited to enhanced diagnosis and awareness, broadened access to treatment, initiatives in research and development, patient advocacy and education, and regulatory sanctions.
In the coming years, the market size for therapeutics related to hereditary angioedema is anticipated to witness a swift expansion. The market is projected to reach “$16.11 billion by 2029, growing at a compound annual growth rate (CAGR) of 19.7%. The significant growth during the predicted period can be credited to enhancements in targeted treatments, the worldwide market’s proliferation, breakthroughs in gene therapy, the trend of personalized medicines, and collaborative efforts in research and cure. The forecast period is set to observe major trends like global reach initiatives, research on health economic outcomes, strategies for early intervention, and therapeutics for pediatric HAE.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10810
Which Cutting-Edge Market Trends Are Expected to Drive theHereditary Angioedema Therapeutics Market’s Growth?
Leading companies in the hereditary angioedema therapeutics market are embracing product innovation as a growing trend. These companies, in an attempt to maintain their market standing, are creating cutting-edge products such as ligand-conjugated (LICA) experimental antisense drugs and gene therapy. For instance, Intellia Therapeutics, a clinical-stage biotechnology firm based in the US, launched a groundbreaking Investigational New Drug (IND) NTLA-2002 in March 2023. This drug was sanctioned by the United States Food and Drug Administration for treating hereditary angioedema, allowing the company to include the US in their existing Phase 1/2 trial onto the global Phase 2 part. The goal is to permanently reduce plasma kallikrein protein activity and impede HAE attacks by incapacitating the target gene, kallikrein B1 (KLKB1), with a singular dose of therapy. Thus, NTLA-2002 is poised as a potential candidate for in vivo genome editing.
What Are the Leading Market Players Impacting theHereditary Angioedema Therapeutics Market’s Growth Trend?
Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.
Order Your Report Now For A Swift Delivery:
How Are the Key Segments of the Hereditary Angioedema Therapeutics Market Driving Opportunities and Innovations?
The hereditary angioedema therapeutics market covered in this report is segmented –
1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Prophylaxis, On-demand
Subsegments:
1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant
2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant
3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab
4) By Other Drug Classes: Emerging Therapies
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=10810&type=smp
What Regions Are At the Forefront of #What Drivers Are Shaping the Growth and Development of theHereditary Angioedema Therapeutics Market?# Market Expansion?
North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Reports Similar to the Gobal Hereditary Angioedema Therapeutics Maret 2025, By The Business Research Company:
Online Therapy Services Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/online-therapy-services-global-market-report
Vitamin D Therapy Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/vitamin-d-therapy-global-market-report
Targeted Therapy Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
